Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 29, 2008

Celera and Abbott Replace Profit-Sharing Terms with Worldwide Distribution and Royalty Arrangements

  • Celera and Abbott revised the terms of their strategic alliance from a profit-sharing arrangement to a distribution and royalty agreement. The distribution deal has an initial term of five years with the potential for two consecutive two-year renewal periods thereafter. The royalty agreement expires in September 2017.

    Abbott will exclusively distribute certain molecular diagnostic products manufactured by Celera. Separately, Celera will receive royalties on the sale of m2000™ reagents, instruments, service, and related consumables, and Abbott will receive royalties on certain Celera genetic tests. The companies will also pay each other royalties on any newly developed products for the m2000 instrument.

    These terms became effective as of October 1 and replace the profit-sharing terms, which were inked in June 2002 and restated in January 2006.

    The agreements reportedly provide more flexibility for Celera and Abbott to develop and commercialize products. The companies will no longer share R&D and SG&A expenses as provided in the previous relationship.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »